Real World Evidence of Fedratinib Effectiveness in MF

Last updated: February 6, 2024
Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto
Overall Status: Active - Recruiting

Phase

N/A

Condition

Post-essential Thrombocythemia Myelofibrosis

Thrombosis

Bone Marrow Disorder

Treatment

Fedratinib

Clinical Study ID

NCT05883904
MPN0123
  • Ages > 18
  • All Genders

Study Summary

This is a multicenter prospective and retrospective observational clinical study in patients with primary or post polycythemia vera or post essential thrombocythemia myelofibrosis to test the efficacy of fedratinib in the rea world. Participants will be managed according to the clinical practice of the participating Center. All Centers will be Italian Hematology Units belonging to the GIMEMA Organization in Italy.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patients aged 18 years or older.
  • Patients diagnosed with primary myelofibrosis [according to the WHO (World HealthOrganization) classification version 5th or the ICC (International ConsensusConference) either published in 2022 or post-polycythemia vera and post-essentialthrombocythemia myelofibrosis (according to the ICC classification 2022)].
  • Patients who met the reimbursement criteria for fedratinib, in accordance with theAIFA (Agenzia Italiana del Farmaco) after June 2022.
  • Patients eligible or not for stem cell transplant (SCT) or patients already undergoingSCT.
  • Patients on non-JAKi cytoreductive treatment.
  • Patients with palpable splenomegaly at baseline of fedratinib treatment.
  • Informed consent signed, if applicable.

Exclusion

Exclusion Criteria:

  • Diagnosis of MPN, unclassifiable, myelodysplastic/myeloproliferative neoplasms,myelodysplastic syndromes, essential thrombocythemia, polycythemia vera.
  • Blast phase of MF.
  • Patients with platelets <50 x10^9/L at baseline of fedratinib treatment.
  • Patients ruxolitinib-exposed for other diseases.

Study Design

Total Participants: 93
Treatment Group(s): 1
Primary Treatment: Fedratinib
Phase:
Study Start date:
January 29, 2024
Estimated Completion Date:
January 31, 2026

Study Description

This is a multicenter prospective and retrospective observational clinical study with the aim of assessing the efficacy of fedratinib upon AIFA approval in patients with primary myelofibrosis or post polycythemia vera or post essential thrombocythemia myelofibrosis. Patients must meet current diagnostic criteria of MF, according to the WHO (World Health Organization) classification version 5th or the ICC (International Consensus Conference) either published in 2022 or post- polycythemia vera and post-essential thrombocythemia myelofibrosis (according to the ICC classification 2022). Patients enter the study at diagnosis or already in follow-up, at any stage of disease, except if transformed to blast phase. Patients who received fedratinib after June 2022 (time of AIFA reimbursement in Italy) will be enrolled and will be included both those ruxolitinib-naïve and ruxolitinib-exposed.

Connect with a study center

  • Ematologia FONDAZIONE IRCCS CA' GRANDA, OSPEDALE MAGGIORE POLICLINICO

    Milano,
    Italy

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.